Trial Profile

A Phase II Study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression Non-Small Cell Non-Squamous Cell Lung Cancer (WJOG10718L Investigator-Initiated Clinical Trial)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms At Be Study; WJOG @Be study

Most Recent Events

14 Mar 2022 Status changed from active, no longer recruiting to completed.
21 Sep 2020 Primary endpoint (Overall response rate (ORR) by central assessment) has been met, according to results presented at the 45th European Society for Medical Oncology Congress
21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com